This trial seeks to prove that sub-lethal laser power levels are as effective and less
damaging than traditional laser. Diabetic macular edema (DME) affects approximately 29% of
diabetic patients with a disease duration of 20 or more years and is one of the most frequent
causes of vision loss in this population. The Early Treatment Diabetic Retinopathy Study
(ETDRS) demonstrated a significant benefit of laser photocoagulation for the treatment of
clinically significant macular edema, reducing the incidence of vision loss by approximately
50% at 3 years' follow-up.